Last update 15 Jul 2024

Loncastuximab tesirine

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Anti-CD19-PBD-conjugate-ADC, Immunoglobulin g1-kappa, anti-(homo sapiens b-lymphocyte antigen cd-19)chimeric monoclonal antibody conjugated to an average of two molecules of tesirine.gamma.1 heavy chain (1-449) (mus musculus vh (ighv1-69*02 (86%) (ighd)-ighj4*01)) (8.8.13) (1-120) -, Lonca
+ [8]
Mechanism
CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), DNA modulators(DNA modulators), DNA alkylating agents
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Conditional marketing approval (EU)
Login to view First Approval Timeline

Structure

Molecular FormulaC42H65N5O17
InChIKeyNPTPHNNPPOZTSM-GSSDHLSPSA-N
CAS Registry-
Boost your research with our XDC technology data.
Boost your research with our XDC technology data.

External Link

KEGGWikiATCDrug Bank
D11338-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diffuse large B-cell lymphoma recurrent
EU
20 Dec 2022
Diffuse large B-cell lymphoma recurrent
IS
20 Dec 2022
Diffuse large B-cell lymphoma recurrent
LI
20 Dec 2022
Diffuse large B-cell lymphoma recurrent
NO
20 Dec 2022
High grade B-cell lymphoma
EU
20 Dec 2022
High grade B-cell lymphoma
IS
20 Dec 2022
High grade B-cell lymphoma
LI
20 Dec 2022
High grade B-cell lymphoma
NO
20 Dec 2022
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
EU
20 Dec 2022
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
IS
20 Dec 2022
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
LI
20 Dec 2022
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
NO
20 Dec 2022
B-Cell Lymphoma
US
23 Apr 2021
Diffuse Large B-Cell Lymphoma
US
23 Apr 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Large B-cell lymphomaNDA/BLA
CN
08 Jun 2023
Large B-cell lymphomaNDA/BLA
CN
08 Jun 2023
Diffuse large B-cell lymphoma refractoryPhase 3
US
16 Sep 2020
Diffuse large B-cell lymphoma refractoryPhase 3
CN
16 Sep 2020
Diffuse large B-cell lymphoma refractoryPhase 3
JP
16 Sep 2020
Diffuse large B-cell lymphoma refractoryPhase 3
AR
16 Sep 2020
Diffuse large B-cell lymphoma refractoryPhase 3
BE
16 Sep 2020
Diffuse large B-cell lymphoma refractoryPhase 3
BR
16 Sep 2020
Diffuse large B-cell lymphoma refractoryPhase 3
CA
16 Sep 2020
Diffuse large B-cell lymphoma refractoryPhase 3
CL
16 Sep 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
50
wccwunereo(lcqkzvutuy) = twyjmvuzom gfuudggnej (ibgarufrjz )
Positive
07 May 2024
Phase 2
145
omnqzxqjbz(ucuyggnokr) = dgffocpopf sapadcveki (exectvhifw, 50.0 - 81.0)
-
01 Apr 2024
Phase 1/2
136
(Phase 1: 60 µg/kg Loncastuximab Tesirine and Ibrutinib)
fcljcuddtk(nvzaovcgyh) = okcwaqatrs bfrjsusszs (gjybqiuqil, aavmvcaqjf - txxuinnvgo)
-
06 Feb 2024
(Phase 1: 75 µg/kg Loncastuximab Tesirine and Ibrutinib)
fcljcuddtk(nvzaovcgyh) = colshohugp bfrjsusszs (gjybqiuqil, amjgykojaq - pgiahethyz)
Phase 1
-
dohvuurooi(fddnhevuot) = The dose-limiting toxicity (DLT) period has been cleared for the first dosing level of ZYNLONTA 90 µg/kg in both arms, wkztzjofxo (dcvqpvhfiu )
Positive
04 Jan 2024
Not Applicable
-
dqvhagmmab(fljgmfqvgu) = jntjbuetnd fspgpkiyia (vynvuhuacr )
Positive
04 Jan 2024
Phase 2
64
mpibhxompi(khmrdvejhy) = fjwrkqmatn fkuojoeaja (kthwxyfezl, 38.7 - 64.2)
Positive
11 Dec 2023
Phase 2
-
dsofliiwcf(tkfmciiyhi) = mbhhwpkewz lazpkyvoml (rdtmzhrhvl )
-
11 Dec 2023
Phase 2
33
ivxhyojuct(jrtwxfgkqy) = pqtavikaaj hifihimkpe (lwfjimavzz )
-
10 Dec 2023
Phase 2
30
hwohyvznib(kkbqxzbcya) = nlulxvrgiw qsbcazhwut (dkbzhnbozl )
-
10 Dec 2023
Phase 2
6
(Loncastuximab Tesirine)
wztcmsgxdi(tsejqogksy) = fxqghsuwrz kmpwomstcp (hfcorbwkjx, ojhotvwpha - jttvagcnld)
-
23 Oct 2023
(Idelalisib)
wztcmsgxdi(tsejqogksy) = sujahakecc kmpwomstcp (hfcorbwkjx, yiwsdlolrj - sqbspghsoc)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free